Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
Minerva Neurosciences, Inc (NASDAQ:NERV) Sees Significant Growth in Short Interest
Minerva Announces Leadership Transition
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
Minerva Neurosciences, Inc. (NERV) Discusses Roluperidone as a Potential First Treatment for Negative Symptoms of Schizophrenia Transcript
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences (NASDAQ:NERV) & UCB (OTCMKTS:UCBJY) Head to Head Analysis
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
US FDA declines to approve Minerva Neurosciences' schizophrenia drug
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences: There's Probably Time For One More Rally
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
What Makes Minerva Neurosciences (NERV) a New Buy Stock
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Minerva Neurosciences, Inc. (NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA
Minerva Neurosciences, Inc. (NERV) Q3 2022 Earnings Call Transcript
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
Minerva Neurosciences to request meeting with FDA about schizophrenia drug
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
TOPS, SURG: The Top 5 Short Squeeze Stocks This Week